Advertisement
Canada markets open in 2 hours 54 minutes
  • S&P/TSX

    21,656.05
    +13.18 (+0.06%)
     
  • S&P 500

    5,022.21
    -29.20 (-0.58%)
     
  • DOW

    37,753.31
    -45.66 (-0.12%)
     
  • CAD/USD

    0.7269
    +0.0005 (+0.07%)
     
  • CRUDE OIL

    81.89
    -0.80 (-0.97%)
     
  • Bitcoin CAD

    84,871.59
    -1,884.41 (-2.17%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,396.90
    +8.50 (+0.36%)
     
  • RUSSELL 2000

    1,947.95
    -19.53 (-0.99%)
     
  • 10-Yr Bond

    4.5850
    0.0000 (0.00%)
     
  • NASDAQ futures

    17,705.00
    +46.50 (+0.26%)
     
  • VOLATILITY

    18.16
    -0.05 (-0.27%)
     
  • FTSE

    7,863.24
    +15.25 (+0.19%)
     
  • NIKKEI 225

    38,079.70
    +117.90 (+0.31%)
     
  • CAD/EUR

    0.6808
    +0.0006 (+0.09%)
     

France says it has ordered 50,000 doses of Merck's COVID-19 antiviral pill

The Merck logo is seen on a sign at the Merck & Co campus in Rahway, New Jersey

PARIS (Reuters) - France has ordered 50,000 doses of Merck & Co's experimental COVID-19 antiviral drug for adults, the country's health minister Olivier Veran told a hearing at the French Senate on Tuesday.

"France positioned itself very early in pre-ordering. France ordered 50,000 doses of the drug," Veran told lawmakers about molnupiravir, which is Merck & Co's experimental antiviral pills to treat COVID-19 ailments.

Governments around the world are preparing to ensure they can cope any pick-up in the COVID virus as the winter season approaches in the northern hemisphere.

Merck & Co said on Monday that the European Union's drug regulator had initiated a real-time review of its experimental COVID antiviral drug for adults.

ADVERTISEMENT

While vaccines are the main weapons against COVID-19, Merck's experimental pill molnupiravir could be a game-changer after studies showed it could halve the chances of dying or being hospitalised for those most at risk of contracting severe illness.

(Reporting by Matthieu Protard; Editing by Sudip Kar-Gupta)